- Home
- Companies
- papua new guinea
- immunotherapy
Show results for
Refine by
Immunotherapy Suppliers Serving Papua New Guinea
89 companies found
based inSan Francisco, CALIFORNIA (USA)
Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell’s mission is to democratize ...
based inAlameda, CALIFORNIA (USA)
Since its inception in 1998, AllCells, a Discovery Life Sciences Company, has focused on advancing science in an innovative, collaborative, and client-centric manner. In our corporate video, AllCells’ Founder, Jay Tong, describes his early days in ...
based inCambridge, MASSACHUSETTS (USA)
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as well as an ...
based inHackensack, NEW JERSEY (USA)
At Champions Oncology, we are passionate about aiding the pharmaceutical industry in developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development ...
based inVirum, DENMARK
Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. Research, development, and commercial ...
Reliable Identification of SARS-CoV-2-Specific T-Cell Responses. T Cells Take the Lead in COVID-19. A deeper understanding of viral-specific T-cell responses to COVID-19 is needed to explore vaccine responses, long-term immunity, predict patients at ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
based inGroningen, NETHERLANDS
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines. Our first product candidate Vvax001, a therapeutic cancer vaccine ...
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in clinical development. We outsource process development and GMP manufacturing to experienced CMO’s, leading to a first ...
based inSeoul, SOUTH KOREA
We make software that transforms medical data into deeper insight. Our AI technology takes medical intelligence to the next level: data-driven medicine. We aim to solve the most critical issues in cancer care today: reduce medical cost and prolong ...
Quantifying PD-L1 positivity with AI analysis; Finding more PD-L1 positive patients; Counting every PD-L1 positive tumor cell; Complex is what AI does ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
based inWoburn, MASSACHUSETTS (USA)
We are an investigational-stage infectious disease company focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections. Using our proprietary technology, we are developing rationally ...
One of the most celebrated achievements of modern medicine is the eradication of the smallpox virus with the use of a live-attenuated vaccine. We are advancing the applied science of attenuating live viruses to develop an entirely new class of ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
NEC OncoImmunity AS has developed an AI engine for its clinical projects, known as the NEC Immune Profiler, that predicts from next generation sequencing data true neoantigens for personalized cancer immunotherapy and cancer ...
based inCambridge, MASSACHUSETTS (USA)
The human body is an ecosystem. Trillions of microbes call us home. They form the human microbiome, which performs critical functions that preserve our health including modulating our immune system and providing colonization resistance against ...
From Ruslan Medzhitov's discovery of toll-like receptors (TLRs) as the key immune system receptors that detect infection, which spawned the field of innate immunity, to Dan Littman's efforts to identify and clone CD4 and CD8, molecules on the ...
based inSyracuse, NEW YORK (USA)
Mesothelioma is an aggressive cancer that affects the lining of the lungs, heart, or abdomen. Caused by the inhalation of asbestos fibers, mesothelioma is often diagnosed in older individuals who worked with asbestos products. Prognosis for ...
There is no cure for mesothelioma, but clinical trials and experimental treatments offer hope for the future. In the never-ending effort to eradicate cancer, there are medical and scientific researchers constantly looking for new ways to attack this ...
based inTokyo, JAPAN
Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of regenerative medicine products as part of the rapid progress of regenerative medicine taking place in the ...
Induced pluripotent stem cells (iPSCs) are established by introducing several factors to somatic cells such as skin cells. iPSCs can differentiate into the cells of a various tissues or organs (pluripotency) and grow indefinitely (proliferation). ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
Pro5® MHC Class I Pentamers the most consistent, most published commercial technology for detecting antigen-specific CD8+ T cells. Pro5® MHC Pentamer. The beautiful rational design of Pro5® MHC Pentamers presents five MHC peptide ...
based inFremont, CALIFORNIA (USA)
BioGenex designs, develops and commercializes molecular pathology systems for Tumor diagnosis, prognosis, precision medicine and life science research. BioGenex’s industry-leading next-generation cytogenetic FISH workflow solution and miRNA system ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to ...